Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects
AIDS 2020
Reported by Jules Levin
Stefaan Rossenu1, Martine Neyens1, Rodica Van Solingen-Ristea1, Bryan Baugh2, Herta Crauwels1
1Janssen Pharmaceutica NV, Research & Development, Beerse, Belgium; 2Janssen Pharmaceutica, Research & Development, Titusville, USA
